CN1507435A - 新型氰基取代的二氢嘧啶化合物及其治疗疾病的用途 - Google Patents
新型氰基取代的二氢嘧啶化合物及其治疗疾病的用途 Download PDFInfo
- Publication number
- CN1507435A CN1507435A CNA028074556A CN02807455A CN1507435A CN 1507435 A CN1507435 A CN 1507435A CN A028074556 A CNA028074556 A CN A028074556A CN 02807455 A CN02807455 A CN 02807455A CN 1507435 A CN1507435 A CN 1507435A
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxo
- dihydro
- cyano group
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995601P | 2001-03-29 | 2001-03-29 | |
| US60/279,956 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1507435A true CN1507435A (zh) | 2004-06-23 |
Family
ID=23071059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028074556A Pending CN1507435A (zh) | 2001-03-29 | 2002-03-26 | 新型氰基取代的二氢嘧啶化合物及其治疗疾病的用途 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6809102B2 (enExample) |
| EP (1) | EP1373221A4 (enExample) |
| JP (1) | JP2005504725A (enExample) |
| KR (1) | KR20030086327A (enExample) |
| CN (1) | CN1507435A (enExample) |
| AR (1) | AR034585A1 (enExample) |
| BG (1) | BG108180A (enExample) |
| BR (1) | BR0208405A (enExample) |
| CA (1) | CA2442482A1 (enExample) |
| CZ (1) | CZ20032645A3 (enExample) |
| EE (1) | EE200300474A (enExample) |
| HR (1) | HRP20030875A2 (enExample) |
| HU (1) | HUP0400350A3 (enExample) |
| IL (1) | IL157441A0 (enExample) |
| IS (1) | IS6967A (enExample) |
| MX (1) | MXPA03008634A (enExample) |
| NO (1) | NO20034300L (enExample) |
| PE (1) | PE20021013A1 (enExample) |
| PL (1) | PL373759A1 (enExample) |
| RU (1) | RU2003130961A (enExample) |
| SK (1) | SK11062003A3 (enExample) |
| TW (1) | TWI228416B (enExample) |
| UY (1) | UY27232A1 (enExample) |
| WO (1) | WO2002079149A2 (enExample) |
| YU (1) | YU75803A (enExample) |
| ZA (2) | ZA200306648B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110464722A (zh) * | 2019-06-06 | 2019-11-19 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| AU2002354465B2 (en) * | 2001-12-11 | 2008-11-20 | Fujifilm Corporation | Thiadiazoline derivative |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| JP3947758B2 (ja) * | 2003-03-07 | 2007-07-25 | アストラゼネカ アクチボラグ | 新規縮合ヘテロサイクル及びその使用 |
| ES2377498T3 (es) * | 2003-04-18 | 2012-03-28 | Kyowa Hakko Kirin Co., Ltd. | Inhibidor de quinesina en etapa M |
| KR20060014071A (ko) * | 2003-06-10 | 2006-02-14 | 교와 핫꼬 고교 가부시끼가이샤 | 티아디아졸린 유도체 |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| US20050282838A1 (en) * | 2003-10-16 | 2005-12-22 | Shyamlal Ramchandani | Compounds, compositions, and methods |
| EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| UY29070A1 (es) * | 2004-08-18 | 2006-03-31 | Astrazeneca Ab | Enantiómeros de heterocíclicos fusionados y sus usos |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| TW200720265A (en) * | 2005-03-22 | 2007-06-01 | Kyowa Hakko Kogyo Kk | Agent for treatment of hematopoietic tumor |
| AU2006225636A1 (en) * | 2005-03-22 | 2006-09-28 | Fujifilm Corporation | Therapeutic agent for solid tumor |
| JPWO2006137490A1 (ja) * | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | 再狭窄治療剤 |
| DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| CA2205384C (en) | 1994-11-16 | 2004-06-29 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| JP2000506904A (ja) | 1996-05-16 | 2000-06-06 | シナプティック・ファーマスーティカル・コーポレーション | ジヒドロピリミジン類およびその使用 |
| WO1998057639A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
| US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| US6346389B1 (en) | 1998-04-01 | 2002-02-12 | Yale University | Method for selectively modulating the interactions between survivin and tubulin |
| US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
| AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| EP1686120A3 (en) | 1999-10-27 | 2007-05-30 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Withdrawn
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en not_active Ceased
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110464722A (zh) * | 2019-06-06 | 2019-11-19 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
| CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BG108180A (en) | 2004-09-30 |
| WO2002079149A3 (en) | 2003-02-27 |
| SK11062003A3 (sk) | 2004-08-03 |
| CA2442482A1 (en) | 2002-10-10 |
| PE20021013A1 (es) | 2002-11-10 |
| CZ20032645A3 (cs) | 2004-06-16 |
| BR0208405A (pt) | 2004-03-30 |
| PL373759A1 (en) | 2005-09-05 |
| IS6967A (is) | 2003-09-24 |
| JP2005504725A (ja) | 2005-02-17 |
| ZA200307320B (en) | 2004-12-20 |
| HRP20030875A2 (en) | 2004-08-31 |
| EP1373221A2 (en) | 2004-01-02 |
| AR034585A1 (es) | 2004-03-03 |
| WO2002079149A2 (en) | 2002-10-10 |
| ZA200306648B (en) | 2004-11-26 |
| EE200300474A (et) | 2003-12-15 |
| MXPA03008634A (es) | 2003-12-08 |
| NO20034300L (no) | 2003-11-07 |
| UY27232A1 (es) | 2002-11-29 |
| US6809102B2 (en) | 2004-10-26 |
| RU2003130961A (ru) | 2005-04-10 |
| US20030008888A1 (en) | 2003-01-09 |
| YU75803A (sh) | 2006-05-25 |
| HUP0400350A2 (hu) | 2005-01-28 |
| KR20030086327A (ko) | 2003-11-07 |
| NO20034300D0 (no) | 2003-09-26 |
| HUP0400350A3 (en) | 2005-06-28 |
| IL157441A0 (en) | 2004-03-28 |
| EP1373221A4 (en) | 2004-09-29 |
| TWI228416B (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1507435A (zh) | 新型氰基取代的二氢嘧啶化合物及其治疗疾病的用途 | |
| CN1105715C (zh) | 新型吡啶酮羧酸衍生物或其盐以及以它们为有效成分的抗菌剂 | |
| CN1230431C (zh) | 用作类胰蛋白酶抑制剂的芳基甲胺衍生物 | |
| CN1034934C (zh) | 血管紧张素ii拮抗性吡啶衍生物的制备方法 | |
| CN1152864C (zh) | 具有pde-iv抑制活性的苯基菲啶类化合物 | |
| CN1038935C (zh) | 取代的联苯吡啶酮化合物及其盐的制备方法 | |
| CN1761671A (zh) | 用作PDE7抑制剂的4－氨基噻吩并[2,3－d]嘧啶－6－甲腈衍生物 | |
| CN1426393A (zh) | 新化合物 | |
| CN1324012C (zh) | TNF－α生成抑制剂 | |
| CN1700918A (zh) | 关于hiv整合酶的n－取代的羟基嘧啶酮甲酰胺抑制剂 | |
| CN1170827C (zh) | 苯并呋喃基吡喃酮衍生物 | |
| CN1832928A (zh) | 以5元杂环为基础的p38激酶抑制剂 | |
| CN100344632C (zh) | 稠合的呋喃化合物 | |
| CN1049219C (zh) | 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物 | |
| CN1034364A (zh) | 取代吡啶和其制备方法 | |
| CN1088207A (zh) | 嘧啶化合物 | |
| CN1518551A (zh) | 三氮杂螺[5,5]十一烷衍生物及包含其作为活性成分的药物组合物 | |
| CN1662498A (zh) | 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物 | |
| CN1290700A (zh) | 苯基哌嗪衍生物 | |
| CN1974574A (zh) | 新的三环螺吡咯烷 | |
| CN1684957A (zh) | 作为组蛋白脱乙酰酶抑制剂的取代的噻吩基－异羟肟酸 | |
| CN1158612A (zh) | 用于治疗变应性疾病的新的取代的哌啶类化合物 | |
| CN1380289A (zh) | 可抑制ApoB－分泌物/MTP的酰胺 | |
| CN1500082A (zh) | 氰基取代的二氢嘧啶化合物及其治疗疾病的用途 | |
| CN1245496A (zh) | 3－吡啶基对映体及其作为镇痛剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |